RPS6KA2 and ovarian carcinoma: While our findings suggest that RPS6KA2 modulates the cisplatin sensitivity in ovarian cancer cells through the regulation of autophagy and ferroptosis, the exact nature of the crosstalk between these two cellular processes remains unclear.